At JP Morgan 2025, pharmaphorum editor-in-chief Jonah Comstock spoke with Ryan Spencer, whose company Dynavax technologies is ...

An inhaled gene therapy for cystic fibrosis developed by Boehringer Ingelheim is due to start clinical testing shortly, hoping to become a first-in-class treatment for the genetic disorder.

Blincyto's label has gradually been extended since 2014, and in December the MHRA approved it as the first immunotherapy for ...

A proposed merger of the UK's Poolbeg Pharma with Austrian biotech Hookipa has been called off after the latter abruptly ...

The week has ended with a flurry of M&A in the drug industry, with Cosette Pharmaceuticals agreeing to buy Australia's Mayne ...

At two Senate confirmation hearings, Kennedy played down his well-publicised questioning of the safety of childhood vaccines ...

Just days after the FDA approved AstraZeneca and Daiichi Sankyo's Enhertu for a potentially lucrative new use, the regulatory has now cleared a diagnostic test that could help unlock the drug's ...

After 2024, which saw a steady recovery by the life sciences industry, it looks like 2025 is set to be a year of change and development, particularly in clinical trials. The good news is that ...

The Trump administration is preparing a new executive order that would seek thousands of layoffs at federal health agencies, including the FDA, according to the Wall Street Journal. Citing people ...

The Trump administration intends to keep only 611 essential workers in position at America's foreign aid agency USAID, according to a notice sent to employees that has been shared with Reuters.

I’ve worked in clinical trials for twenty years. For most of that time, the core processes and challenges have been fairly consistent, with incremental improvements along the way. That’s all ...

AstraZeneca has unveiled plans to invest around $570 million in Canada and add around 700 new jobs, describing the county as a "growing global hub" for clinical trials. The C$820 million ...